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Spencer A. W. Lee1,2, Luciano A. Sposato3,4,5, Vladimir Hachinski3,6 and Lauren E. Cipriano1,6*

Abstract
Background: Accurate and timely diagnosis of Alzheimer’s disease (AD) is important for prompt initiation of treatment
in patients with AD and to avoid inappropriate treatment of patients with false-positive diagnoses.
Methods: Using a Markov model, we estimated the lifetime costs and quality-adjusted life-years (QALYs) of cerebrospinal
fluid biomarker analysis in a cohort of patients referred to a neurologist or memory clinic with suspected AD who
remained without a definitive diagnosis of AD or another condition after neuroimaging. Parametric values were
estimated from previous health economic models and the medical literature. Extensive deterministic and
probabilistic sensitivity analyses were performed to evaluate the robustness of the results.
Results: At a 12.7% pretest probability of AD, biomarker analysis after normal neuroimaging findings has an incremental
cost-effectiveness ratio (ICER) of $11,032 per QALY gained. Results were sensitive to the pretest prevalence of AD, and the
ICER increased to over $50,000 per QALY when the prevalence of AD fell below 9%. Results were also sensitive to patient
age (biomarkers are less cost-effective in older cohorts), treatment uptake and adherence, biomarker test characteristics,
and the degree to which patients with suspected AD who do not have AD benefit from AD treatment when they are
falsely diagnosed.
Conclusions: The cost-effectiveness of biomarker analysis depends critically on the prevalence of AD in the tested
population. In general practice, where the prevalence of AD after clinical assessment and normal neuroimaging findings
may be low, biomarker analysis is unlikely to be cost-effective at a willingness-to-pay threshold of $50,000 per QALY
gained. However, when at least 1 in 11 patients has AD after normal neuroimaging findings, biomarker analysis is likely
cost-effective. Specifically, for patients referred to memory clinics with memory impairment who do not present
neuroimaging evidence of medial temporal lobe atrophy, pretest prevalence of AD may exceed 15%. Biomarker
analysis is a potentially cost-saving diagnostic method and should be considered for adoption in high-prevalence centers.
Keywords: Alzheimer’s disease, Cost-effectiveness analysis, Cerebrospinal fluid biomarkers, Neuroimaging

Background
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder currently affecting an estimated 36 million
people globally, with prevalence predicted to double in
the next 10 years [1–3]. In the United States alone, with
5.2 million patients with AD [4], total direct costs in
2014 were estimated to be $214 billion, with another
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$220 billion in unpaid care [1]. Accurate and timely
diagnosis of AD is important to initiate treatment
promptly and to avoid inappropriate therapeutic interventions in patients with false-positive diagnoses [5].
Even though current treatments (acetylcholinesterase inhibitors and memantine) do not reverse the underlying
neurological damage, AD treatments can delay cognitive
and functional decline and improve overall quality of life
[6, 7]. Several studies have found AD treatments to be
cost-effective in mild to moderate AD and moderate to
severe AD [8–11].
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Clinical diagnosis of AD has a relatively low and highly
uncertain diagnostic accuracy [12, 13]. To aid in diagnosis,
neuroimaging by computed tomography (CT) or magnetic
resonance imaging (MRI) is typically performed, both to
rule out non-AD causes of cognitive impairment, such as
meningioma and subdural hematoma, and to evaluate
structural indicators of AD, including medial temporal
lobe (MTL) atrophy [14]. Still, these neuroimaging techniques do not provide the desired level of accuracy to
confidently diagnose AD in a considerable proportion of
patients. Single-photon emission computed tomography
(SPECT), 18F-fluorodeoxyglucose positron emission
tomography (PET), and amyloid PET are effective at
ruling out a diagnosis of neurodegenerative disease and
amyloid-β (Aβ) deposition in the brain, but the results
are complex, difficult to interpret, and have low to moderate positive predictive value, especially in older patients
because brain Aβ deposition increases with age [14–16].
Cerebrospinal fluid (CSF) biomarkers have demonstrated relatively high diagnostic accuracy even for prodromal AD in patients with mild cognitive impairment
(MCI) [14, 15] and so may provide additional diagnostic
insight. However, CSF collection involves a lumbar
puncture, which has an associated cost and causes patient discomfort.
Previous cost-effectiveness analyses of AD diagnostic
technologies present conflicting findings potentially attributable to differences in the clinical setting of the
diagnosis being considered [17, 18]. In two studies performed in the early 2000s, researchers found the
addition of SPECT and PET to clinical assessment was
not cost-effective [19, 20]. Authors of a recent costeffectiveness analysis compared clinical assessment plus
florbetapir-PET with clinical assessment alone and found
the addition of florbetapir-PET to be cost-effective from
the perspective of the Spanish National Health System
[21]. However, they did not compare PET with a standard diagnostic regimen including CT or MRI analysis.
Researchers in a cost minimization study, also performed from the perspective of the Spanish National
Health System, suggested that the use of CSF biomarkers
may reduce AD-related health care costs [22]. However,
that study did not account for the discomfort and risks
of undergoing lumbar puncture or improvements in
quality of life for patients accurately diagnosed with AD.
In the present study, we evaluated the cost-effectiveness
of performing CSF biomarker analysis in a cohort of patients with suspected dementia who were referred to a
neurologist or memory clinic and who remained without
a definitive diagnosis after neuroimaging.

Methods
We developed a Markov model to evaluate the lifetime
costs and benefits of performing CSF biomarker analysis
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in patients referred to a neurologist or memory clinic
with suspected dementia who, after evaluation by neuroimaging, do not have a definitive diagnosis of AD or
another cause of dementia (Fig. 1a). In 1-month time
steps, the model followed the diagnosis and health state
progression of a hypothetical cohort of patients. We
used standard health economic methods by taking a societal perspective, considering costs and benefits over a
lifetime horizon, discounting costs and benefits at 3%
annually, and performing both probabilistic and deterministic sensitivity analysis to evaluate the robustness of
our findings [23]. For determining cost-effectiveness, we
used the commonly applied thresholds of $50,000 and
$100,000 per quality-adjusted life-year (QALY) gained
[24]. We implemented the model in Microsoft Excel 2013
using Visual Basic for Applications (Microsoft Corp.,
Seattle, WA, USA).
Model overview

A schematic of the model is presented in Fig. 1. We considered two diagnostic strategies: biomarker analysis and
do nothing. Patients were divided into four groups on
the basis of their true health state and diagnosed health
state: true-positive, false-negative, false-positive, and
true-negative (Fig. 1b). Similar to previously published
model-based analyses of AD [19], individuals who had
AD were divided into 12 health states on the basis of the
severity of their disease, whether or not they were on
treatment, and their location (Fig. 1c). In the base case
analysis, we assumed that patients who did not have AD
had another disease causing stable MCI, so individuals
who did not have AD were divided into four health
states on the basis of whether they were on AD treatment (because of false diagnosis) and their type of residence (Fig. 1d). We performed structural sensitivity
analysis exploring alternative assumptions for the natural
history for the non-AD patients, including modeling it
as a stable, moderate cognitive impairment and as a
progressive cognitive impairment with transition rates
similar to AD.
In each month, patients could die or transition from
one health state to another. We estimated the rate of
transition between disease states, the influence of treatment on those transitions, as well as costs and utilities
associated with each health state from the medical literature (Table 1). When multiple sources were available
to inform parameters, we selected studies that were
more generalizable to the modeled population (i.e.,
large, U.S.-based cohorts) and those using more recent
datasets. When the literature reported conflicting evidence or wide uncertainty, we selected a central value
for the base case and performed extensive sensitivity
analysis over the entire range of values reported in the
literature. We validated model outcomes by replicating
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Fig. 1 Patient cohort and decision model. a Flowchart of patients referred to a memory clinic or neurology practice with suspected dementia,
some of whom would be diagnosed with probable AD after clinical assessment and MRI. If MRI does not provide a definitive non-AD diagnosis
for any patients, and if all patients remain candidates for biomarker analysis, the pretest prevalence of AD is 12.7%. If MRI provides a definitive
non-AD diagnosis for some patients, the pretest prevalence of AD in the cohort patients who continue to have suspected AD is greater than
12.7%. b Schematic of a decision tree. The blue square represents the decision whether to use CSF biomarkers. Green circles represent chance
events. The population is divided into four groups on the basis of whether the patients have Alzheimer’s disease and the outcome of the diagnostic
strategy: true-positive, false-negative, false-positive, and true-negative. The proportion of patients in each group is determined by the prevalence of AD
in the evaluated cohort and the sensitivity and specificity of each diagnostic strategy. c Markov model of Alzheimer’s disease. Patients begin in the
health states for community-dwelling mild, moderate, and severe AD. Each month, patients may die, progress or regress in terms of disease severity,
discontinue or reinitiate treatment, transition from living in the community to living in a long-term care facility, or stay in the same health state. In the
model, patients living in a long-term care facility cannot return to living in the community. d Markov model for patients with non-AD dementia.
Patients begin in the community-dwelling non-AD dementia state. Only those with a false-positive diagnosis of AD receive AD treatment. Each month,
patients may die, discontinue or reinitiate treatment, transition from living in the community to living in a long-term care facility, or stay in the same
health state. AD Alzheimer’s disease, BM Biomarker, CSF Cerebrospinal fluid, MRI Magnetic resonance imaging, MTL Medial temporal lobe, SN Sensitivity,
SP Specificity

the analysis of previously published model-based costeffectiveness studies of AD diagnosis [20, 25].
Data and assumptions
Patient cohort

The prevalence of AD in a cohort of patients with possible dementia varies across referral centers and increases with patient age and family history [1]. Of the
8495 patients referred to 30 U.S. Alzheimer’s disease
centers, 24% were diagnosed with mild AD [26]. We estimated the true prevalence to be 21%, adjusting for the
accuracy of diagnosis with clinical assessment and MRI
(as the status quo), where proportion diagnosed = prevalence × sensitivity + (1 − prevalence) × (1 − specificity).

Clinical assessment and MTL atrophy seen on MRI
would help identify approximately half of the patients
with AD in the referral population (sensitivity of memory impairment plus MRI is 54% [13]). Accounting for
the diagnosis of AD after MRI, the approximate prevalence of AD in the remaining patients is 12.7% (Fig. 1a).
In addition, MRI may provide another definitive diagnosis where the possibility of concomitant AD is highly unlikely and thus further consideration of AD using
biomarkers is no longer clinically relevant. This patient
selection will increase the pretest prevalence of AD (by
which we mean the probability of AD in the cohort of
patients with memory impairment, no abnormal MTL
atrophy, and no alternative diagnosis precluding AD) in
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Table 1 Base case inputs, ranges for sensitivity analysis, and sources
Parameter

Base case

Low value

High value

Source [reference]

65

55

75

[4]

70

0.5400

0.783

[67]

Patient population
Start age, years
Initial AD severity distribution (%)
Mild
Moderate

28

0.1850

0.427

[67]

Severe

2

0.0170

0.033

[67]

Diagnosis
Diagnostic test accuracy
Status quo: clinical assessment plus MR neuroimaging (CA + MR)
Sensitivity (SNMR)

0.54

0.46

0.62

[13]

Specificity (SPMR)

0.84

0.79

0.89

[13]

Revised criteria: clinical assessment plus MR neuroimaging and/or biomarker analysis
Sensitivity (SNMR+BM)

0.86

0.80

0.92

[13]

Specificity (SPMR+BM)

0.79

0.74

0.84

[13]

Diagnostic accuracy of CSF biomarkers in patients with no medial temporal lobe atrophy on MRI
Sensitivity (SNBM|MR−)

0.698

0.54

0.86

Calculateda

Specificity (SPBM|MR−)

0.941

0.89

0.98

Calculateda

Biomarker analysis

(see Methods)

Cost

463

250

600

[50]

QALY toll

−0.008

0

−0.02

[19, 57]

AD natural history model
Mortality
Annual mortality rate = 3.53e0.0909×Age

Estimatedb [53, 68]

Mild

2.92

2.34

3.52

[29]

Moderate

3.85

2.94

5.05

[29]

Severe

9.52

6.60

13.4

[29]

Age-specific mortality due to causes other than AD
HRs for AD-specific mortality

Disease progression without AD treatment (annual rate per 100,000)
From mild
To moderate

27,710

24,939

30,481

[25, 31]

To severe

1385

1247

1524

[25, 31]

To mild

4478

4030

4925

[25, 31]

To severe

31,829

28,647

35,012

[25, 31]

To mild

385

347

424

[25, 31]

To moderate

5332

4799

5865

[25, 31]

From moderate

From severe

Transition to long-term care facility (annual rate per 100,000)
From mild

2110

500

4000

[31, 43, 44]

From moderate

6957

1500

8000

[31, 43, 44]

From severe

11,747

2500

15,000

[31, 43, 44]
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Table 1 Base case inputs, ranges for sensitivity analysis, and sources (Continued)
AD treatment
Treatment uptake and adherence
Treatment initiation
Donepezil, at diagnosis

0.45

0.27

0.56

[37, 39, 41]

Memantine, at transition to severe AD

0.36

0.22

0.45

[38]

Donepezil, community dwelling

28,768

10,536

35,667

[36]

Donepezil, long-term care facility dwelling

62,362

51,083

69,315

[42]

Memantine

30,111

12,783

44,629

[6]

Donepezil

33,142

23,105

40,132

[38]

Memantine

22,314

17,834

25,541

[6]

Transition from mild to moderate

0.5

0.253

0.989

[25]

Transition from moderate to mild

2.36

0.802

6.95

[25]

Transition from community to long-term care facility

0.37

0.2

0.5

[43]

Incremental utility (annualized)

0.051

0

0.1

[7]

HR, transition from community to long-term
care facility

0.37

0.2

0.5

Assumed same as donepezil

Treatment discontinuation (annual rate per 100,000)

Treatment reinitiation after quitting (annual rate per 100,000)

Treatment effectiveness
Donepezil HRs

Memantine

Costs (US$)
Age-specific baseline costs

Annual costs = 893e0.0404×Age

Estimated (see Methods)

45–64 years

5499

4000

8000

[51]

65–84 years

12,336

11,000

16,000

[51]

>84 years

27,674

25,000

34,000

[51]

Annual incremental costs by disease severity (including costs of informal caregiving)
Community dwelling
Patients without AD

24,128

17,369

30,369

Assumed the same as Mild AD

Mild AD

24,128

17,369

30,369

(see Additional file 1)

Moderate AD

33,845

25,000

40,000

(see Additional file 1)

Severe AD

60,160

50,000

69,000

(see Additional file 1)

Facility cost

83,950

70,000

95,000

[52]

Patients without AD

9872

7000

12,000

Assumed the same as Mild AD

Mild AD

9872

7000

12,000

(see Additional file 1)

Moderate AD

9872

7000

12,000

(see Additional file 1)

Severe AD

9847

7000

12,000

(see Additional file 1)

Donepezil, 10 mg/day

2473

2000

4288

[69]

Memantine, 10 mg/day

3192

2500

5957

[69]

<90 years

35,158

32,000

39,500

[70]

>90 years

25,455

22,000

28,000

[70]

Long-term care facility dwelling

Medication (annual)

Age-specific annual health care costs in the year of death
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Table 1 Base case inputs, ranges for sensitivity analysis, and sources (Continued)
Utilities
Age-specific weights

[54, 55]

60–64 years

0.83

0.822

0.835

65–69 years

0.82

0.820

0.826

70–74 years

0.81

0.803

0.818

75–79 years

0.79

0.786

0.794

>79 years

0.74

0.730

0.742

Health state-specific weights
Community dwelling
Patients without AD

0.68

0.52

0.80

Assumed same as mild AD

Mild AD

0.68

0.52

0.80

[25]

Moderate AD

0.54

0.30

0.70

[25]

Severe AD

0.37

0.25

0.50

[25]

Patients without AD

0.71

0.55

0.80

Assumed same as mild AD

Mild AD

0.71

0.55

0.80

[25]

Moderate AD

0.48

0.30

0.60

[25]

Severe AD

0.31

0.20

0.45

[25]

Long-term care facility dwelling

Abbreviations: AD Alzheimer’s disease, BM Biomarker, CA Clinical assessment, CSF Cerebrospinal fluid, MR Magnetic resonance, MRI Magnetic resonance imaging,
QALY Quality-adjusted life-year, SN Sensitivity, SP Specificity
a
The sensitivity of biomarker analysis in patients without abnormal medial temporal lobe atrophy on MRI (SNBM|MR-) was calculated using the sensitivity of the
revised criteria (in which patients are diagnosed with AD if they have abnormal findings on MRI or abnormal biomarkers, denoted SNMR+BM) and the sensitivity of
clinical assessment and MRI alone (SNMR) using the formula: SNMR+BM = SNMR + (1 − SNMR) × SNBM|MR−.The specificity of biomarker analysis in patients without
abnormal medial temporal lobe atrophy on MRI (SPBM|MR−) was calculated using the specificity of the revised criteria (SPMR+BM) and the specificity of clinical
assessment and MRI alone (SPMR) using the formula: SPMR+BM = SPMR × SPBM|MR−
b
To avoid double-counting the deaths caused by AD, the age-specific mortality rate due to AD was subtracted from the all-cause mortality rate using an excess
mortality model. The resulting “other-cause” age-specific mortality rate was smoothed using an exponential fit

patients still considered candidates for biomarker analysis. Specifically, if 10%, 20%, or 40% of non-AD patients are correctly identified as having an alternative
diagnosis (and not having AD) after MRI, then the pretest prevalence of AD increases to 14%, 15%, or 19%,
respectively. Furthermore, if patients without memory
impairment are excluded, the prevalence of AD in the
cohort of patients considered for biomarker analysis increases to 39% (the sensitivity and specificity of memory
impairment alone are 93% and 68%, respectively [13]).
Variation in the case mix across referral centers, including
the prevalence of AD and the distribution of causes for
non-AD dementia, creates high uncertainty in the prevalence of AD in patients who remain without a definitive
diagnosis after neuroimaging. Therefore, base case results are presented over the full range of possible AD
prevalence.
Diagnostic accuracy

Bouwman et al. retrospectively evaluated the diagnostic
accuracy of clinical assessment plus neuroimaging by
MR and the revised AD diagnostic criteria [27] in 138
patients with AD and 223 memory clinic patients without AD [13]. Under the revised AD diagnostic criteria,

patients were defined as having AD when clinical assessment indicated episodic memory impairment and either
evidence of MTL atrophy and/or an abnormal biomarker profile [13, 27]. MTL atrophy was scored visually
on a scale of 0 (no atrophy) to 4 (severe atrophy) for
both left and right hippocampi and then averaged to
generate a single score. Positive AD findings were based
on age-specific thresholds: ≥1 was considered abnormal
for patients aged <65 years; ≥1.5 was considered abnormal
for patients aged 65–75 years; and >2 was considered abnormal for patients >75 years of age. For CSF biomarker
analysis, CSF was obtained using a standard lumbar puncture procedure and measured by commercially available
sandwich enzyme-linked immunosorbent assays. Positive
AD findings based on CSF biomarkers required at least
two of the three biomarker criteria to be satisfied: low
Aβ42 concentrations (<495 ng/L), increased total tau concentrations (>356 ng/L), or increased phospho-tau concentrations (>54 ng/L). (For further information, refer to
Bouwman et al. [13].)
We calculated the sensitivity and specificity of biomarker analysis performed in patients without evidence
of MTL atrophy on MRI by solving for the values that
would achieve the overall sensitivity and specificity
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observed using the revised AD diagnostic criteria. In
sensitivity analyses, we considered a wide range of values
for biomarker sensitivity and specificity after a normal
MRI, with sensitivity ranging from 54% to 86% (base
case 69.6%) and specificity ranging from 89% to 98%
(base case 94.1%).
Mortality

All-cause mortality was estimated using 2009 U.S. life
tables [28]. To estimate the total mortality rate for a patient
with AD at each stage of the disease, we multiplied the
age-specific mortality rate for death due to other causes by
AD severity-specific mortality HRs [29]. In our model, AD
treatments did not influence mortality, because an analysis
of the National Alzheimer’s Coordinating Center (NACC)
Uniform Data Set indicated that AD treatment did not influence the rate of death after adjusting for disease severity
and other factors influencing treatment use [30].
Natural history of AD

Transition rates between AD severity health states and
between living in the community to living in a long-term
care facility (LTCF) were estimated using the NACC
Uniform Data Set [31]. Despite the progressive nature of
AD, this analysis and a similar analysis of the Consortium
to Establish a Registry for Alzheimer’s Disease dataset estimated a positive probability of transitioning backward
(e.g., from moderate to mild AD) [32]. Possible explanations for backward transition include variation in clinical
presentation and assessment, concomitant disease, and
treatment adjustments resulting in noisy observations over
time or masking the true disease severity [32]. We used
the severity-specific proportion of patients with AD on
acetylcholinesterase inhibitor treatment and the HRs for
progression on treatment to calculate treatment-stratified
transition rates (details in Additional file 1: Section 1.1).
Treatment regimens, adherence, and efficacy

Treatment dosage and schedule were incorporated in accordance with various guidelines: donepezil 10 mg per
day in mild and moderate AD [33–35] and memantine
10 mg per day in severe AD [33]. We represented all
acetylcholinesterase inhibitors with donepezil because it
is the most commonly prescribed of these drugs [36].
Acetylcholinesterase inhibitor uptake rates vary significantly across study cohorts, with initiation rates ranging
from 27% [37] to 97% [38] in newly diagnosed patients
with AD in the community. We estimated a moderate uptake rate of 45% on the basis of a study of communitydwelling patients who screened positive for dementia in a
primary care setting [39]. Specialized or coordinated care
increases treatment uptake rates [40]; therefore, we considered uptake rates from 27% to 56% in sensitivity analysis [37, 41]. Base case treatment discontinuation and
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reinitiation rates were informed by large observational
cohorts such that 25% of community-dwelling patients
and 46.4% of facility-dwelling patients discontinued AD
treatment each year [36, 42], and 63% of communitydwelling patients and 36% of facility-dwelling patients
who had discontinued AD treatments restarted treatment within 1 year [6, 38].
Consistent with previous model-based analyses of AD,
acetylcholinesterase inhibitor treatment reduced the
transition rate from mild AD to moderate AD and increased the transition rate from moderate AD to mild
AD [25]. The benefit of memantine treatment was incorporated into our model by an improved quality of life
for patients with severe AD by 0.051 QALYs per year,
which we estimated on the basis of average improvement in activities of daily living reported in a metaanalysis [7]. In the base case, consistent with previously
published model-based analyses of AD treatment [25],
we assumed that donepezil treatment does not reduce
the rate of transition between moderate and severe disease,
although we explored this possibility in sensitivity analysis.
In the model, patients not on AD treatment are 2.7 times
more likely to transition to an LTCF, as specifically reported by authors of a large U.S. medical claims database
analysis including more than 5000 patients with AD [43]
and consistent with other literature reports [31, 44–46].
In the base case analysis, patients without AD received
no benefits from AD treatment, but we varied this assumption in sensitivity analysis. Occupational or psychosocial treatments were not included in the model,
because they likely incur similar costs and provide benefits to patients with AD dementia and non-AD dementia
[47–49].
Costs

We identified the clinical visit and laboratory testing
codes with the Healthcare Common Procedure Coding
System (HCPCS) and Current Procedural Terminology
(CPT), then we estimated their cost using the 2013
Medicare reimbursement schedule [50]. We assumed biomarker analysis required a lumbar puncture procedure for
the collection of CSF (CPT code 62270), an immunoassay
analysis (HCPCS code 83520), and a follow-up visit with a
neurologist in which the diagnosis is reported (CPT code
99213), resulting in a total cost of $463.
In each month, individuals accrued age-specific health
care costs unrelated to AD, additional AD severityspecific health care costs, and location-specific (community
or LTCF) supportive care costs (paid and unpaid). Agespecific health care costs unrelated to AD, including
out-of-pocket health care expenses, were based on the
U.S. national average, which we smoothed using an exponential fit with a cap at the average annual cost of
$33,870 for patients aged 90 years and older [51]. AD
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severity-specific costs of inpatient care, outpatient care,
emergency care, and unpaid caregiving are detailed in
Additional file 1: Section 1.2. The annual cost of living
in an LTCF was estimated to be $83,950 (in 2013 U.S.
dollars), based on the U.S. national average cost of a
semiprivate room in a nursing home [52]. Costs were
adjusted for inflation to constant 2013 U.S. dollars
using the gross domestic product deflator [53].
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(denoted λ) is greater than 0. The INMB comparing the
two tests is calculated as

λ QALYTruePositive −QALYFalseNegative
− CostTruePositive −CostFalseNegative


þð1−pÞðr2 −q2 Þ λ QALYTrueNegative −QALYFalsePositive
− CostTrueNegative −CostFalsePositive


INMB ¼ pðr1 −q1 Þ

−ΔTestCost−λΔTestQALY

Quality of life

We estimated baseline age-specific utilities from the
Medical Expenditure Panel Survey data [54, 55]. Ageand AD severity-specific utilities were incorporated into
the model by multiplying the age-specific utility by the
AD severity-specific utility. Utility weights for each AD
disease state were estimated on the basis of a prior costeffectiveness analysis [25]. To our knowledge, no study
to date has evaluated the one-time utility toll associated
with embarrassment and discomfort before, during, and
after a diagnostic test requiring lumbar puncture, including
the risk and consequences of lumbar puncture-associated
moderate to severe headache [56]. We assumed the onetime reduction in quality of life associated with lumbar
puncture is approximately the same as the reduction in
quality of life associated with breast biopsy, which has been
measured to be equivalent to 2.92 quality-adjusted lifedays (annualized to a one-time toll of 0.008 QALY incurred
at the time of the test) [57].
Analysis

We calculated the average lifetime discounted costs and
QALYs for each diagnostic outcome and for each diagnostic strategy. If neither strategy cost less and provided
more QALYs than the other, we calculated the incremental cost-effectiveness ratio (ICER). In a probabilistic
analysis, we ran 10,000 independent simulations in which
inputs were selected randomly from the probability distributions described in Additional file 1: Section 1.3 to determine 95% CIs for each outcome. We also performed
deterministic sensitivity analyses to evaluate the robustness of our findings to uncertainty in model parameters
and assumptions.
To provide general insight into the test characteristics
that would make a new test or test combination both
clinically and economically attractive after MRI, we
identified the “challenge region” as described by Phelps
and Mushlin at the willingness-to-pay (WTP) thresholds of $50,000 and $100,000 per QALY gained [58].
The boundary of the challenge region is identified as
any set of new test characteristics, sensitivity r1 and
specificity r2 , for which the incremental net monetary
benefit (INMB) compared with the current technology,
with sensitivity q1 and specificity q2 , at the WTP threshold

where p is the prevalence of the disease, r1  q1 is
the improvement (or reduction) in sensitivity, r2  q2
is the improvement (or reduction) in specificity,





λ QALYTruePositive  QALYFalseNegative  CostTruePositive  CostFalseNegative

is the INMB of preventing a false-negative diagnosis,





λ QALYTrueNegative  QALYFalsePositive  CostTrueNegative  CostFalsePositive

is the INMB of preventing a false-positive diagnosis,
ΔTestCost is the difference in cost between the new
and old diagnostic strategies, and ΔTestQALY is the
difference in the short-term quality-of-life effects associated with the test strategy.

Results
Lifetime costs and benefits of each diagnostic outcome

The lifetime discounted costs and QALYs associated with
each possible diagnosis are shown in Table 2. Accurate
diagnosis of AD decreased lifetime discounted costs by
$9954 and increased lifetime QALYs by 0.248. In non-AD
patients, a false diagnosis of AD increased lifetime costs
by $11,345 due to unnecessary treatment costs.
Effectiveness and cost-effectiveness of diagnostic
alternatives

At a 12.7% pretest probability of AD, biomarker analysis increased the average cost per patient by $165
(95% CI −$1865 to $1625) and increased the average
QALYs per patient by 0.015 (95% CI −0.011 to 0.051).
The relatively small gain in QALYs was due primarily
to the short-term discomfort associated with the lumbar puncture procedure (−0.008 QALY), which was experienced by all patients. At this pretest probability of
AD, the ICER of biomarker analysis was $11,032 per
QALY gained (Fig. 2a). Probabilistic analysis identified
extremely high uncertainty: a 40% probability that biomarker analysis will decrease costs and increase QALYs,
and a 7% probability that it will do the opposite (increase
costs and decreased QALYs). Overall, at an expected pretest prevalence of 12.7%, biomarkers were identified as
cost-effective in 72% of simulations using a WTP threshold of $50,000 per QALY gained and 82% of simulations
using a WTP threshold of $100,000 per QALY gained
(Fig. 2b).
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Table 2 Average per-patient lifetime discounted costs and quality-adjusted life-years, by diagnostic outcome and strategy
Cost (U.S.$)

LYs

QALYs

Probability of each outcome

Lifetime discounted costs and benefits by diagnostic outcome
AD
True-positive

$298,632

6.781

2.916

8.9%

False-negative

$308,586

6.555

2.660

3.8%

False-positive

$294,732

9.157

5.048

5.2%

True-negative

$283,387

9.157

5.048

82.1%

Not AD

Lifetime discounted costs and benefits by diagnostic strategy
Do nothing

$286,587 (244,438 to 337,270)

4.745 (3.88 to 5.42)

Biomarker analysis (BM)

$286,752 (244,044 to 337,163)

4.760 (3.89 to 5.44)

Incremental (BM vs. do nothing)

$165 (−1865 to 1625)

Incremental cost-effectiveness ratio ($ per QALY gained)

0.015 (−0.011 to 0.051)
$11,032a

Abbreviations: AD Alzheimer’s disease, LY Life-year, QALY Quality-adjusted life-year
a
The empiric distribution of incremental cost-effectiveness ratios (ICERs) over the 10,000 simulations identified a 40% probability that biomarker analysis (BM) will
decrease costs and increase QALYs and a 7% probability that BM will increase costs and decrease QALYs, assuming an average AD prevalence of 12.7%. Therefore,
the 95% CI over the ICER ranges from BM is cost-saving to BM is dominated. Empiric 95% CIs were estimated from 10,000 simulations in which all input parameters were
varied simultaneously

The results are highly influenced by the pretest prevalence of AD (Fig. 3a and b). The ICER rapidly increases
as the pretest prevalence decreases (Fig. 3a); for pretest
prevalence less than 9.1%, biomarker analysis costs more
than $50,000 per QALY gained, and for pretest prevalence less than 7.5%, biomarker analysis costs more than
$100,000 per QALY gained. For higher pretest prevalence, the ICER for biomarkers rapidly decreases, and
for a pretest prevalence exceeding 15%, the probability
that biomarkers are cost-effective is 74%, and deterministic analysis indicates biomarkers are cost-saving.
Deterministic sensitivity analysis

At a pretest prevalence greater than 9%, deterministic
sensitivity analysis indicated that biomarker analysis

continued to be cost-effective within the ranges of uncertainty to disease progression rates, the rate of transition from living in the community to living in an LTCF,
the cost of care in an LTCF, and the cost of biomarker
testing. However, at a base case pretest prevalence of
12.7%, our findings were sensitive to patient age, rate of
transition into an LTCF, the costs of long-term care, test
performance, and treatment adherence (Additional file 1:
Table S3). High rates of AD treatment adherence decrease
the cost-effectiveness of biomarker analysis because they
increase the costs associated with false-positive diagnoses.
However, in a sensitivity analysis in which we considered
that AD treatment may provide 50% of the benefit to
patients with a false-positive diagnosis [59, 60], biomarker
analysis costs more than $50,000 per QALY gained.

Fig. 2 a Cost-effectiveness plane: incremental costs and incremental QALYs of CSF biomarker analysis. b Probability of each diagnostic strategy
being the cost-effective alternative at various willingness-to-pay thresholds when all model input parameters are varied simultaneously. AD Alzheimer’s
disease, BM Biomarker, CA Clinical assessment, MR Magnetic resonance, QALY Quality-adjusted life-year
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We relied heavily on the study of Bouwman et al. to
estimate the sensitivity and specificity of biomarker
analysis [13]. However, this study had relatively small
sample size and used a gold standard of multidisciplinary
team consensus rather than autopsy, the only true gold
standard in AD diagnosis [61]. As such, we considered a
wide range of sensitivities and specificities lower than in
our base case (Additional file 1: Table S3). At moderately
lower diagnostic accuracy (sensitivity 62%, specificity
92%), biomarker analysis remains the preferred alternative. At a low diagnostic accuracy (sensitivity 54%,
specificity 89%), the ICER of biomarker analysis increases to $87,000 per QALY gained. Lowering the specificity further (sensitivity 54%, specificity 84%), the ICER of
biomarker analysis exceeds $100,000 per QALY gained.
Additionally, there is uncertainty about the proportion of
patients who would receive a definitive non-AD diagnosis
prior to biomarker analysis, which would increase the pretest prevalence of AD in the tested cohort. In this case of
very low test accuracy, if AD prevalence in the tested cohort is 15%, the ICER is $87,600 per QALY gained.
Two-way sensitivity analysis of prevalence and age revealed that, for younger patients, biomarker analysis is
cost-effective at pretest probabilities of AD less than 8%
at WTP of $50,000 per QALY gained (Fig. 4a). For older

Fig. 3 a Incremental cost effectiveness ratio (in U.S. dollars per QALY
gained) of biomarker analysis for various pre-test probabilities of AD.
b Incremental cost effectiveness ratio at various pre-test probabilities
of AD. AD Alzheimer's disease, BM Biomarker, ICER Incremental
cost-effectiveness ratio, QALY Quality-adjusted life-year
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patients, such as those over the age of 75 years, biomarker
analysis is cost-effective only in highly selected patient cohorts with pretest prevalence >27% and >20% at WTP of
$50,000 or $100,000 per QALY gained, respectively (i.e.,
those with memory impairment). Two-way sensitivity
analysis also identified that either increasing the cost of
biomarker analysis by $1400 or increasing the utility
decrement by 0.020 QALYs was sufficient for biomarker
analysis to no longer be cost-effective (Fig. 4b).
Structural sensitivity analysis on the natural history of
non-AD patients indicated that biomarker analysis is
slightly more cost-effective if the conditions affecting patients without AD are more severe than we assumed in
our base case. Biomarker analysis is less cost-effective if
patients without AD but who are falsely diagnosed with
AD receive a small benefit from acetylcholinesterase inhibitor treatment (Additional file 1: Table S3). Biomarker
analysis is also less cost-effective if correction is made
when disease progresses for patients with initially falsenegative results (Additional file 1: Table S3).
Challenge region

When developing a diagnostic test, a trade-off exists between test sensitivity and specificity. In the case of AD,
improved test sensitivity prevents delay in access to
quality-of-life treatments caused by false-negative diagnoses (valued at $9954 per false-negative avoided), and
improved test specificity prevents unnecessary treatment
resulting from false-positive diagnoses (valued at $11,345
per false-positive avoided). The challenge region presented
in Fig. 5 identifies the collection of all sensitivity and specificity pairs where a hypothetical test, with a cost and
short-term disutility similar to those of CSF biomarkers,
would be cost-effective compared with no test at four
levels of pretest prevalence: 7.5%, 12.7%, 15%, and 30%.

Discussion
For biomarker analysis to be cost-effective at a WTP of
$50,000 per QALY gained, the pretest prevalence of AD
in the tested cohort must be more than 1 in 11 patients.
Overall prevalence of AD in the referral population varies
substantially across referral centers, with specialized centers diagnosing AD in approximately one-fourth of referred patients [26, 61]. Evaluation of MTL atrophy by
MRI will diagnose at least half of patients with AD. MRI
may also identify a definitive diagnosis other than AD,
which may preclude the need for continued evaluation in
some patients. The optimal policy may therefore vary
across clinics and may further depend on specific patient
risk factors. In patients presenting to memory clinics with
memory impairment without MTL atrophy, AD pretest
prevalence may be greater than 14.5%; in these patients,
biomarker analysis has the potential to be cost-saving. In
addition to the benefits measured in the present study,
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Fig. 4 Two-way sensitivity analyses simultaneously varying (a)
patient age and pre-test probability of AD and (b) utility detriment
from lumbar puncture and the cost of biomarker analysis. Triangle:
base case; White area: Cost saving at willingness-to-pay of 50,000
per QALY gained; Grey area: ICER of 50,000 100,000 per QALY
gained; Black area: ICER> 100,000 per QALY gained. AD Alzheimer's
disease, ICER Incremental cost-effectiveness ratio, QALY Quality-adjusted
life-year

timely diagnosis would also enable patients and their
families to make informed decisions in planning future
caregiving at a time when all parties achieve the greatest
benefit and enable patients to have a greater role in
making their own health care decisions before cognitive
impairment interferes [62].
In practice, treatment uptake and adherence are low
[63]. However, even with very low rates of treatment uptake and high rates of treatment discontinuation, biomarker
analysis remains the preferred alternative (Additional file 1:
Table S3). However, if patients without AD who receive a
false-positive diagnosis of AD (and therefore initiate treatment at the same rates as patients with a true-positive diagnosis of AD) receive moderate benefits from donepezil and
memantine for a disease with a similar progression to AD,
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Fig. 5 Challenge region. The challenge region identifies the test
sensitivity-specificity combinations for a hypothetical new test, with
a similar cost and short-term disutility as CSF biomarkers, that would be
cost-effective compared to no test at four levels of pre-test prevalence:
7.5% (black area), 12.7% (dark grey area), 15% (medium grey area), and
30% (light grey area). The test accuracy of CSF biomarkers (white
triangle) is also plotted for ease of comparing its test accuracy to
the challenge region. (a) Willingness to pay threshold of 50,000 per
QALY gained; (b) Willingness to pay threshold of 100,000 per QALY
gained. CSF cerebrospinal fluid, WTP Willingness-to-pay, QALY
Quality-adjusted life-year

biomarker analysis is no longer the cost-effective option at
a WTP of $50,000 per QALY gained (Additional file 1:
Table S3). This finding indicates that if patients with a
false-positive diagnosis, for whom the cost of treatment will
be incurred, receive a benefit from that treatment, the economic benefit derived from reducing the number of falsepositives decreases. This finding does not indicate that
donepezil or memantine treatment for patients without
AD is necessarily cost-effective. The cost-effectiveness
of cholinesterase inhibitor treatment in patients with
non-AD disease has been demonstrated for Lewy body
dementia [64], but acetylcholinesterase inhibitors have
not shown clinical benefit for patients with MCI [65].
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In general, the cost-effectiveness of a treatment depends on the natural history of the disease as well as
the cost and efficacy of all treatment alternatives available to patients with that condition.
Studies in which researchers have estimated the diagnostic accuracy of clinical assessment, neuroimaging,
and CSF biomarkers vary widely in their findings [66].
We used the study by Bouwman et al., who retrospectively
applied each potential diagnostic strategy to 138 patients
with AD and 223 memory clinic patients without AD [13].
Relying on a single study provided internally consistent estimates for the sensitivity and specificity of each test and
the tests compared with each other, which may not have
occurred had we collected test accuracy information
from independent studies performed with different patient populations. At low pretest probabilities (<9%),
the incremental cost of biomarker analysis was not robust to the uncertainty in test accuracy or many other
input parameters. However, at higher pretest probabilities, the finding that biomarkers are cost-effective is
robust to uncertainty in biomarker test accuracy (Fig. 5).
This is relevant because specificity in particular may
vary across referral centers, depending on the mix of
patients composing the non-AD cohort. Greater confidence in the accuracy of diagnostic strategies can be
established with larger sample size studies similar in design to that of Bouwman et al., in which multiple diagnostic criteria were applied to the same patients [13].
Our analysis has limitations, including a limited number
of health states that do not fully represent the complex
and multifaceted nature of AD and other neurological or
psychiatric diseases represented in the non-AD population
[18]. However, in addition to modeling cognitive functional decline, we included whether the patient was
dwelling in the community or in an LTCF to incorporate elements of functional dependence, and we included
disease severity-specific unpaid caregiving. Our inputs
were derived from the medical literature. Specifically,
transition rates for AD progression were based on an
observational cohort not stratified by treatment status.
In addition, several model parameters, including the accuracy of both diagnostic strategies, relied on studies
with relatively small sample sizes and AD diagnosis
based on clinical assessment, not on autopsy.

Conclusions
Biomarker testing reduces the number of false-negative
diagnoses and therefore connects patients to treatment
earlier, improving their quality of life. Although the costeffectiveness of biomarker analysis depends critically on
the prevalence of AD in the tested population, it is costeffective at a WTP of $50,000 per QALY gained in patient cohorts in which at least 1 (9%) in 11 patients has
AD. In patients presenting to memory clinics with memory
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impairment without neuroimaging evidence of MTL atrophy, AD prevalence likely exceeds 15%. Biomarker analysis
is potentially cost-saving and should be considered for
adoption in high-prevalence centers.

Additional file
Additional file 1: Cost-effectiveness of cerebrospinal biomarkers for
Alzheimer’s diagnosis: supplemental Methods, Results, figures and tables
as referenced in the text. (DOCX 91 kb)
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